Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
1 hedge funds and large institutions have $0 invested in Keryx Biopharmaceuticals Inc in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 121 closing their positions.
61.74% less ownership
Funds ownership: 61.74% → 0% (-62%)
99% less funds holding
Funds holding: 122 → 1 (-121)
100% less capital invested
Capital invested by funds: $253M → $0 (-$253M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 121
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$87.7M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$31M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$28M |
| 4 |
BlackRock
New York
|
-$24.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$17.5M |
KERX Hedge Fund Activity: Q4 2018 in Review
1 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2018, worth a combined $0 — down 100% from $253M a quarter earlier.
Sellers outnumbered buyers: 121 funds closed out of KERX and 0 opened new positions — a net loss of 121 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Baupost Group, exiting entirely with an estimated $87.7M sold.
- 1 institutional investor held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2018, down from 122 in Q3 2018.
- Funds reported $0 of Keryx Biopharmaceuticals Inc stock for Q4 2018, down 100% quarter-over-quarter.
- 0 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2018 and 121 closed out, a net change of -121 holders.
- The largest Keryx Biopharmaceuticals Inc seller in Q4 2018 was Baupost Group, an estimated $87.7M sold.
Based on aggregated 13F filings for Q4 2018.